Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 4/20 | 0.45 |
| ▸ | PREP | P48147 | 3/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6379511 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9AAGTR2 | |
| SCHEMBL1287227 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1NPC1RAB9AAGTR2 | |
| SCHEMBL2916597 | 0.95 | FKBP1A (0.49) | SMN1; SMN2ALDH1A1NPC1RAB9AAGTR2 | |
| SCHEMBL1697453 | 0.88 | SPHK1 (0.46) | SMN1; SMN2ALDH1A1NPC1RAB9AAGTR2 | |
| SCHEMBL7390923 | 0.88 | SPHK1 (0.54) | SMN1; SMN2NPC1RAB9APREPSPHK1 | |
| SCHEMBL10961572 | 0.87 | HTR2A (0.44) | PREPSPHK1FKBP1A | |
| SCHEMBL3578383 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1NPC1RAB9AACE | |
| SCHEMBL5158304 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1NPC1RAB9AACE | |
| SCHEMBL7427948 | 0.85 | CCR4 (0.46) | SMN1; SMN2ALDH1A1PREPFKBP1A | |
| SCHEMBL7427947 | 0.85 | CCR4 (0.46) | SMN1; SMN2ALDH1A1PREPFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011060832-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1003775-B1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM CA LTD (CA) | 2005-03-16 | — | — | EP | disclosed |
| EP-1012180-B1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM CA LTD (CA) | 2004-12-01 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1012180-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-06-28 | — | — | EP | disclosed |
| EP-1003775-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007733-A2 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999007734-A2 | HEPATITIS C INHIBITOR PEPTIDE ANALOGUES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-02-18 | — | — | WO | disclosed |
| EP-0273399-B1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI SEIYAKU CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| EP-0439444-A2 | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-07-31 | — | — | EP | disclosed |
| US-5013842-A | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors | MONSANTO COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| US-4895944-A | BACTERICIDE OFLOXACIN | DAIICHI SEIYAKU COMPANY, LTD. (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0273399-A1 | Optically active 2,3-dihydrobenzoaxine derivatives and process for preparing the same | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-4494547-A | 2H-isoindolediones, their synthesis and use as radiosensitizers | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 1985-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | SMN1; SMN2 2375/4885ALDH1A1 2056/4885NPC1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.